Kirk A. Frey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kirk A. Frey has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Nicolaas I. Bohnen
Department of Radiology, University of Michigan , Ann Arbor, MI 48109
4 shared publications - Satoshi Minoshima
Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT
3 shared publications Timothy J. Desmond
Mental Health Research Institute, University of Michigan, Ann Arbor, MI
3 shared publications- Allen Frederick Brooks
University of Michigan Medical School
2 shared publications Masahiko Suzuki
Department of Radiology (Nuclear Medicine), University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0028, USA
2 shared publications- Peter James Henry Scott
Department of Radiology, University of Michigan, Ann Arbor, USA
2 shared publications
Latest Publications
- Open Access
- 12 December 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (12) , 1711
GABAA Receptor Benzodiazepine Binding Sites and Motor Impairments in Parkinson’s Disease
Flumazenil is an allosteric modulator of the γ-aminobutyric acid-A receptor (GABAAR) benzodiazepine binding site that could normalize neuronal signaling and improve motor impairments in Parkinson’s disease (PD). Little is known about how regional GABAAR availability affects motor symptoms. We investigated the relationship between regional availability of GABAAR benzodiazepine binding sites and motor impairments in PD. Methods: A total of 11 Patients with PD (males; mean age 69.0 ± 4.6 years; Hoehn and Yahr stages 2–3) underwent [11C]flumazenil GABAAR benzodiazepine binding site and [11C]dihydrotetrabenazine vesicular monoamine transporter type-2 (VMAT2) PET imaging and clinical assessment. Stepwise regression analysis was used to predict regional cerebral correlates of the four cardinal UPDRS motor scores using cortical, striatal, thalamic, and cerebellar flumazenil binding estimates. Thalamic GABAAR availability was selectively associated with axial motor scores (R2 = 0.55, F = 11.0, β = −6.4, p = 0.0009). Multi-ligand analysis demonstrated significant axial motor predictor effects by both thalamic GABAAR availability (R2 = 0.47, β = −5.2, F = 7.2, p = 0.028) and striatal VMAT2 binding (R2 = 0.30, β = −3.9, F = 9.1, p = 0.019; total model: R2 = 0.77, F = 11.9, p = 0.0056). Post hoc analysis demonstrated that thalamic [11C]methyl-4-piperidinyl propionate cholinesterase PET and K1 flow delivery findings were not significant confounders. Findings suggest that reduced thalamic GABAAR availability correlates with worsened axial motor impairments in PD, independent of nigrostriatal degeneration. These findings may augur novel non-dopaminergic approaches to treating axial motor impairments in PD.
- 12 December 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (12) , 1711
Open AccessGABAA Receptor Benzodiazepine Binding Sites and Motor Impairments in Parkinson’s Disease
Flumazenil is an allosteric modulator of the γ-aminobutyric acid-A receptor (GABAAR) benzodiazepine binding site that could normalize neuronal signaling and improve motor impairments in Parkinson’s disease (PD). Little is known about how regional GABAAR availability affects motor symptoms. We investigated the relationship between regional availability of GABAAR benzodiazepine binding sites and motor impairments in PD. Methods: A total of 11 Patients with PD (males; mean age 69.0 ± 4.6 years; Hoehn and Yahr stages 2–3) underwent [11C]flumazenil GABAAR benzodiazepine binding site and [11C]dihydrotetrabenazine vesicular monoamine transporter type-2 (VMAT2) PET imaging and clinical assessment. Stepwise regression analysis was used to predict regional cerebral correlates of the four cardinal UPDRS motor scores using cortical, striatal, thalamic, and cerebellar flumazenil binding estimates. Thalamic GABAAR availability was selectively associated with axial motor scores (R2 = 0.55, F = 11.0, β = −6.4, p = 0.0009). Multi-ligand analysis demonstrated significant axial motor predictor effects by both thalamic GABAAR availability (R2 = 0.47, β = −5.2, F = 7.2, p = 0.028) and striatal VMAT2 binding (R2 = 0.30, β = −3.9, F = 9.1, p = 0.019; total model: R2 = 0.77, F = 11.9, p = 0.0056). Post hoc analysis demonstrated that thalamic [11C]methyl-4-piperidinyl propionate cholinesterase PET and K1 flow delivery findings were not significant confounders. Findings suggest that reduced thalamic GABAAR availability correlates with worsened axial motor impairments in PD, independent of nigrostriatal degeneration. These findings may augur novel non-dopaminergic approaches to treating axial motor impairments in PD.
- 28 January 2022
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 49 (6) , 2098-2099
PET imaging of metastatic paraganglioma using novel 3-[18F]fluoro-para-hydroxyphenethylguanidine (3-[18F]pHPG) radiotracer
- 28 January 2022
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 49 (6) , 2098-2099
PET imaging of metastatic paraganglioma using novel 3-[18F]fluoro-para-hydroxyphenethylguanidine (3-[18F]pHPG) radiotracer
- 1 May 2021
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 51 (3) , 275-285
Molecular Imaging of Extrapyramidal Movement Disorders With Dementia: The 4R Tauopathies
- 1 May 2021
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 51 (3) , 275-285
Molecular Imaging of Extrapyramidal Movement Disorders With Dementia: The 4R Tauopathies
- 1 April 2021
- Published by Elsevier in PET Clinics
- Vol. 16 (2) , 261-272
Molecular Imaging of Neurodegenerative Parkinsonism
- 1 April 2021
- Published by Elsevier in PET Clinics
- Vol. 16 (2) , 261-272
Molecular Imaging of Neurodegenerative Parkinsonism
- 14 August 2017
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 17 (10) , 1-9
Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias
Purpose of Review The aims of the study were to review recent advances in molecular imaging in the Lewy body dementias (LBD) and determine if these may support the clinical but contested temporal profile distinction between Parkinson disease (PD) with dementia (PDD) versus dementia with Lewy bodies (DLB). Recent Findings There do not appear to be major regional cerebral metabolic or neurotransmitter distinctions between PDD and DLB. However, recent studies highlight the relative discriminating roles of Alzheimer proteinopathies. PDD patients have lower cortical β-amyloid deposition than DLB. Preliminary tau PET studies suggest a gradient of increasing tau binding from cognitively normal PD (absent to lowest) to cognitively impaired PD (low) to DLB (intermediate) to Alzheimer disease (AD; highest). However, tau binding in DLB, including the medial temporal lobe, is substantially lower than in AD. Summary Alzheimer-type proteinopathies appear to be more common in DLB compared to PDD with relative but no absolute differences. Given the spectrum of overlapping pathologies, future α-synuclein ligands are expected to have the best potential to distinguish the LBD from pure AD.
- 14 August 2017
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 17 (10) , 1-9
Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias
Purpose of Review The aims of the study were to review recent advances in molecular imaging in the Lewy body dementias (LBD) and determine if these may support the clinical but contested temporal profile distinction between Parkinson disease (PD) with dementia (PDD) versus dementia with Lewy bodies (DLB). Recent Findings There do not appear to be major regional cerebral metabolic or neurotransmitter distinctions between PDD and DLB. However, recent studies highlight the relative discriminating roles of Alzheimer proteinopathies. PDD patients have lower cortical β-amyloid deposition than DLB. Preliminary tau PET studies suggest a gradient of increasing tau binding from cognitively normal PD (absent to lowest) to cognitively impaired PD (low) to DLB (intermediate) to Alzheimer disease (AD; highest). However, tau binding in DLB, including the medial temporal lobe, is substantially lower than in AD. Summary Alzheimer-type proteinopathies appear to be more common in DLB compared to PDD with relative but no absolute differences. Given the spectrum of overlapping pathologies, future α-synuclein ligands are expected to have the best potential to distinguish the LBD from pure AD.
- Open Access
- 6 June 2017
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 2 (1) , 1-13
An updated radiosynthesis of [18F]AV1451 for tau PET imaging
[18F]AV1451 is a commonly used radiotracer for imaging tau deposits in Alzheimer’s disease (AD) and related non-AD tauopathies. Existing radiosyntheses of [18F]AV1451 require complex purifications to provide doses suitable for use in clinical imaging studies. To address this issue, we have modified the synthesis of [18F]AV1451 to use only 0.5 mg precursor, optimized the Boc-deprotection step and developed a simplified method for HPLC purification of the radiotracer. An optimized [18F]AV1451 synthesis using a TRACERLab FXFN module led to high radiochemical yield (202 ± 57 mCi per synthesis) and doses with excellent radiochemical purity (98 ± 1%) and good specific activity (2521 ± 623 Ci/mmol). An updated and operationally simple synthesis of [18F]AV1451 has been developed that is fully automated and prepares radiotracer doses suitable for use in clinical tau PET studies.
- 6 June 2017
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 2 (1) , 1-13
Open AccessAn updated radiosynthesis of [18F]AV1451 for tau PET imaging
[18F]AV1451 is a commonly used radiotracer for imaging tau deposits in Alzheimer’s disease (AD) and related non-AD tauopathies. Existing radiosyntheses of [18F]AV1451 require complex purifications to provide doses suitable for use in clinical imaging studies. To address this issue, we have modified the synthesis of [18F]AV1451 to use only 0.5 mg precursor, optimized the Boc-deprotection step and developed a simplified method for HPLC purification of the radiotracer. An optimized [18F]AV1451 synthesis using a TRACERLab FXFN module led to high radiochemical yield (202 ± 57 mCi per synthesis) and doses with excellent radiochemical purity (98 ± 1%) and good specific activity (2521 ± 623 Ci/mmol). An updated and operationally simple synthesis of [18F]AV1451 has been developed that is fully automated and prepares radiotracer doses suitable for use in clinical tau PET studies.
- 1 January 2017
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 47 (1) , 18-30
Molecular Imaging of Extrapyramidal Movement Disorders
- 1 January 2017
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 47 (1) , 18-30
Molecular Imaging of Extrapyramidal Movement Disorders
- 1 January 2017
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 47 (1) , 2-4
Updates in Molecular Brain Imaging
- 1 January 2017
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 47 (1) , 2-4
Updates in Molecular Brain Imaging
- 14 April 2016
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 57 (8) , 1168-1169
PET Amyloid Analyses
- 14 April 2016
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 57 (8) , 1168-1169
PET Amyloid Analyses
- 9 July 2015
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 56 (9) , 1467
Reply: Alzheimer Disease: Approaches to Early Diagnosis and High-Accuracy Imaging.
- 9 July 2015
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 56 (9) , 1467
Reply: Alzheimer Disease: Approaches to Early Diagnosis and High-Accuracy Imaging.